US2017267733A1PendingUtilityA1
Novel Read-Through Fusion Polynucleotides and Polypeptides and Uses Thereof
Individually held — no corporate assignee on recordPriority: Oct 14, 2012Filed: Nov 17, 2016Published: Sep 21, 2017
Est. expiryOct 14, 2032(~6.2 yrs left)· nominal 20-yr term from priority
Inventors:Katherine E. VarleyRichard M. MyersBrian S RobertsJason GertzDonald J. BuchsbaumAndres Forero-TorresAlbert F. Lobuglio
G01N 33/57515C07K 14/4748C07K 14/47G01N 33/57415
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A purified antibody that binds specifically to the polypeptides of SEQ ID. NO. 4, SEQ ID. NO. 5, SEQ ID NO. 6 or SEQ ID NO: 7.Join the waitlist — get patent alerts
Track US2017267733A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.